Pharmacists in Traverse City, Michigan
143 Pharmacists found in Traverse City
Mr. James Christian Michutka, RPH
Pharmacist
550 Munson Ave, Suite G100, Traverse City, MI 49686
231-935-8730
Mr. James Whitney Bock, R. PH.
Pharmacist
4000 Eastern Sky Dr., Suite 1, Traverse City, MI 49684
231-947-6921
Mr. James R Wolff, PHARMACIST
Pharmacist
111 E Front St, Traverse City, MI 49684
231-946-4830 231-946-7847
James Denzel Carpenter, RPH
Pharmacist
550 Munson Ave Ste G-100, Traverse City, MI 49686
231-935-8730 231-935-8741
Ms. Jane Lee Conard, RPH
Pharmacist
Munson Medical Center, 1105 Sixth St, Traverse City, MI 49684
231-935-6586
Dr. Jennifer Dawn Sterling, PHARM.D.
Pharmacist
3900 N Us 31 S, Traverse City, MI 49684
231-922-9277
Jennifer Rebecca Dykstra, PHARM.D.
Pharmacist
550 Munson Ave, Suite G100, Traverse City, MI 49686
231-935-8730
Jessica Jackline Bradley, PHARM.D.
Pharmacist
3955 Us 31 S, Traverse City, MI 49684
231-933-1810 231-933-1865
Ms. Joanne Perry Mcgurn, RPH, BCOP
Pharmacist - Oncology
1105 6th St, Traverse City, MI 49684
231-935-6734 231-935-7017
John Wallace Weih, RPH
Pharmacist
3850 N Long Lake Rd, Traverse City, MI 49684
231-947-2880 231-947-2907
Dr. Judith S Christensen, PHARM.D.
Pharmacist - Pharmacotherapy
1105 6th St, Munson Medical Center Pharmacy Dept, Traverse City, MI 49684
231-935-7651 231-935-5667
Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.